Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.426, 2003-01, pp. : 3-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Biological agents cost effective in the treatment of RA
Inpharma, Vol. 1, Iss. 1402, 2003-01 ,pp. :
Access to resources
Recommend
Infliximab may be cost effective in severe, treatment-resistant RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 480, 2005-01 ,pp. :
Infliximab may be cost effective in severe, treatment-resistant RA
Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. :
Etanercept considered cost effective vs DMARDs in RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 446, 2004-01 ,pp. :
Economics of biological agents for RA weighed up
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 630, 2011-01 ,pp. :